ArticleBiomolecules2021

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.

Xiuman Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.